Powered by 
Google Übersetzer
Google Übersetzer
18 November 2025
Physiomics plc
("Physiomics" or the "Company")
Result of AGM
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today, were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.
Details of the proxy voting results are shown in the table below.
|
Ordinary Resolutions |
Votes For |
% |
Votes Against |
% |
Votes Withheld |
Votes Total |
% of ISC Voted |
|
|
1 |
Approval of the accounts |
27,842,565 |
98.8% |
314,631 |
1.1% |
3,461 |
28,160,657 |
9.3% |
|
2 |
Re-election of Dr Jim Millen as a Director of the Company |
26,622,673 |
94.6% |
1,510,182 |
5.4% |
27,802 |
28,160,657 |
9.3% |
|
3 |
Re-election of Dr Tim Corn as a Director of the Company |
26,586,162 |
94.5% |
1,546,693 |
5.5% |
27,802 |
28,160,657 |
9.3% |
|
4 |
Appointment and renumeration of auditor |
27,774,713 |
98.6% |
375,483 |
1.3% |
10,461 |
28,160,657 |
9.3% |
|
5 |
Authority to allot shares |
24,190,035 |
85.9% |
2,007,140 |
7.1% |
1,963,482 |
28,160,657 |
9.3% |
|
Special Resolution |
|
|
|
|
|
|
|
|
|
6 |
Disapplication of shareholders' statutory pre-emption rights |
23,055,357 |
81.9% |
3,141,818 |
11.2% |
1,963,482 |
28,160,657 |
9.3% |
ISC - Issued Share Capital
For more information about Physiomics and its services, please visit www.physiomics.co.uk.
Enquiries:
Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 140 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
